Rankings
▼
Calendar
CTNM Q2 2023 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$504M
Q2 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$50M
Gross Profit
$50M
99.9% margin
Operating Income
$39M
77.9% margin
Net Income
$42M
83.1% margin
EPS (Diluted)
$1.62
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
$41M
Free Cash Flow
$41M
Stock-Based Comp.
$489,000
← FY 2023
All Quarters
Q3 2023 →
